Hepion Pharmaceuticals, INC 8-K filings

Hepion Pharmaceuticals, Inc. has entered into securities purchase agreements to sell shares and warrants in a private placement, raising gross proceeds of $3,055,000.

Hepion Pharmaceuticals, Inc. announced the immediate appointment of Danina Fisher and Gary S. Stetz, II to its Board of Directors.

Hepion Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, and an amendment to the equity incentive plan.

Hepion Pharmaceuticals has entered into a private placement agreement to issue 17.5 million shares of common stock for $700,000 in gross proceeds.

Hepion Pharmaceuticals, Inc. reports on the separation agreement with former CEO Dr. Kaouthar Lbiati, detailing severance payments and her resignation from the board.

Hepion Pharmaceuticals, Inc. announced the immediate resignation of its CEO, Dr. Kaouthar Lbiati, and the appointment of Gary Stetz as interim CEO, alongside new board members.

Hepion Pharmaceuticals secures a license for a novel circulating tumor RNA biomarker assay from Cirna Diagnostics to enhance early diagnosis of hepatocellular carcinoma.

Hepion Pharmaceuticals, Inc. announced the appointment of Dr. Kaouthar Lbiati as its new Chief Executive Officer, effective January 8, 2026, detailing her compensation and severance package.

Hepion Pharmaceuticals, Inc. announced the resignation of John Brancaccio as Chief Financial Officer and a director, effective June 30, 2025, for personal reasons.

Hepion Pharmaceuticals, Inc. announced the results of its 2025 Annual Meeting of Stockholders, revealing shareholder rejection of proposals for a reverse stock split and executive compensation, while ratifying the appointment of independent auditors.

Hepion Pharmaceuticals, Inc. announced the appointment of Dr. Kaouthar Lbiati, a current director, as interim Chief Executive Officer, effective June 16, 2025.

Hepion Pharmaceuticals, Inc. has entered into an agreement to sell all Rencofilstat-related assets to Panetta Partners Limited for a nominal amount, retaining contingent value rights for future milestone payments.

Hepion Pharmaceuticals receives notification of delisting from Nasdaq due to failure to meet minimum bid price and concerns about being a public shell, transitioning to OTC Markets Group.

Hepion Pharmaceuticals enters a binding agreement to in-license diagnostic tests for various diseases, including celiac disease and hepatocellular carcinoma, from New Day Diagnostics LLC.

Hepion Pharmaceuticals received a delisting notice from Nasdaq due to concerns about the company's status as a public shell.

Hepion Pharmaceuticals files an amendment to its previous 8-K report to update its balance sheet as of January 31, 2025, following a determination regarding the accounting and valuation of Series A and Series B warrants issued in a recent offering.

Hepion Pharmaceuticals received a delisting notice from Nasdaq after its stock price remained below $0.10 for ten consecutive business days.

Hepion Pharmaceuticals enacted a 1-for-50 reverse stock split of its common stock, effective March 17, 2025.

Hepion Pharmaceuticals held its 2024 Annual Meeting of Stockholders on March 10, 2025, and announced the results of voting on five proposals, including the election of directors, ratification of auditors, executive compensation, warrant share issuance, and a reverse stock split amendment.

Hepion Pharmaceuticals issued its unaudited consolidated balance sheet as of January 31, 2025, showcasing its financial position.

Hepion Pharmaceuticals received a notice from Nasdaq for failing to hold an annual shareholder meeting within twelve months of its fiscal year end, potentially leading to delisting.

Hepion Pharmaceuticals has terminated its merger agreement with Pharma Two B due to Nasdaq's burn rate calculation, leading to the cancellation of a special stockholder meeting.

Hepion Pharmaceuticals received a notice from Nasdaq for failing to meet continued listing requirements due to a stockholders' deficit reported in its recent quarterly filing.

Hepion Pharmaceuticals has received a notice from Nasdaq stating that its stock price has fallen below the required $1 minimum, putting its listing at risk.

Hepion Pharmaceuticals' interim CEO and CFO, John Cavan, has departed for personal reasons, with executive chairman John Brancaccio stepping in as interim CEO and CFO effective August 6, 2024.

Hepion Pharmaceuticals will merge with Pharma Two B, a late-clinical stage company developing a Parkinson's disease treatment, and secure $11.5 million in private financing.

Hepion Pharmaceuticals has appointed Michael Purcell as a new director and chair of the Audit Committee, effective March 5, 2024.

Hepion Pharmaceuticals reports the resignation of Dr. Gary Jacob from the Board of Directors and the appointment of John Brancaccio as the new Chairman, effective February 20, 2024.

Hepion Pharmaceuticals has entered into a warrant inducement agreement, resulting in approximately $2.06 million in gross proceeds through the exercise of existing warrants at a reduced price.

Anand Reddi resigned from Hepion Pharmaceuticals' Board of Directors, effective February 7, 2024.